Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm

Neurobiology of Disease

Volumn 97, Issue , 2017, Pages 139-155

  Josephy Hernandez, Sylvia ^a,b   Jmaeff, Sean ^a,b   Pirvulescu, Iulia ^a,b   Aboulkassim, Tahar ^a   Saragovi, H Uri ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Mimetic; Neurodegeneration; Neurotrophin; Receptor; Small molecule; Therapy

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 7,8 DIHYDROXYFLAVONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMITRIPTYLINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR AGONIST; BRIMONIDINE; CILIARY NEUROTROPHIC FACTOR; DAPICLERMIN; DEOXYGEDUNIN; GAMBOGIC ACID; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IDEBENONE; NERVE GROWTH FACTOR; NEUROTROPHIN; NEUROTROPHIN RECEPTOR; NEUROTROPHIN RECEPTOR AGONIST; NEUROTROPHIN RECEPTOR ANTAGONIST; NEUROTROPHIN RECEPTOR P75; NEURTURIN; NORASTERRIQUINONE B1; PAECILOMYCINE A; PROTEIN RET; PROTEIN TYROSINE KINASE A; RECEPTOR BLOCKING AGENT; RILUZOLE; RUTOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XALIPRODEN; NERVE GROWTH FACTOR RECEPTOR; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DIABETIC RETINOPATHY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; GLAUCOMA; HUMAN; HUNTINGTON CHOREA; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; SYNTHESIS;

ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, NERVE GROWTH FACTOR;

EID: 84994188990     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.08.004     Document Type: Review

References (264)

1. Aboulkassim, T., Tong, X.K., Tse, Y.C., Wong, T.P., Woo, S.B., Neet, K.E., Brahimi, F., Hamel, E., Saragovi, H.U., Ligand-dependent TrkA activity in brain differentially affects spatial learning and long-term memory. Mol. Pharmacol. 80 (2011), 498–508.
2. Adamiec-Mroczek, J., Zajac-Pytrus, H., Misiuk-Hojlo, M., Caspase-dependent apoptosis of retinal ganglion cells during the development of diabetic retinopathy. Adv. Clin. Exp. Med. 24 (2015), 531–535.
3. Alberch, J., Perez-Navarro, E., Canals, J.M., Neurotrophic factors in Huntington's disease. Prog. Brain Res. 146 (2004), 195–229.
4. Ali, T.K., Matragoon, S., Pillai, B.A., Liou, G.I., El-Remessy, A.B., Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes 57 (2008), 889–898.
5. Ali, T.K., Al-Gayyar, M.M., Matragoon, S., Pillai, B.A., Abdelsaid, M.A., Nussbaum, J.J., El-Remessy, A.B., Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia 54 (2011), 657–668.
6. Allen, S.J., Watson, J.J., Shoemark, D.K., Barua, N.U., Patel, N.K., GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther. 138 (2013), 155–175.
7. Al-Shawi, R., Hafner, A., Chun, S., Raza, S., Crutcher, K., Thrasivoulou, C., Simons, P., Cowen, T., ProNGF, sortilin, and age-related neurodegeneration. Ann. N. Y. Acad. Sci. 1119 (2007), 208–215.
8. Alzheimer's, A., 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 11 (2015), 332–384.
9. Ames, P., Galor, A., Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence. Clin. Investig. 5 (2015), 267–285.
10. Anderson, D.R., Hendrickson, A., Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve. Investig. Ophthalmol. 13 (1974), 771–783.
11. Appel, S.H., A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann. Neurol. 10 (1981), 499–505.
12. Aveleira, C.A., Lin, C.M., Abcouwer, S.F., Ambrosio, A.F., Antonetti, D.A., TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 59 (2010), 2872–2882.
13. Bai, Y., Dergham, P., Nedev, H., Xu, J., Galan, A., Rivera, J.C., ZhiHua, S., Mehta, H.M., Woo, S.B., Sarunic, M.V., Neet, K.E., Saragovi, H.U., Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism. J. Biol. Chem. 285 (2010), 39392–39400.
14. Bai, Y., Shi, Z., Zhuo, Y., Liu, J., Malakhov, A., Ko, E., Burgess, K., Schaefer, H., Esteban, P.F., Tessarollo, L., Saragovi, H.U., In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death. Invest. Ophthalmol. Vis. Sci. 51 (2010), 6639–6651.
15. Bai, Y., Xu, J., Brahimi, F., Zhuo, Y., Sarunic, M.V., Saragovi, H.U., An agonistic TrkB mAb causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma. Invest. Ophthalmol. Vis. Sci. 51 (2010), 4722–4731.
16. Balaiya, S., Edwards, J., Tillis, T., Khetpal, V., Chalam, K.V., Tumor necrosis factor-alpha (TNF-alpha) levels in aqueous humor of primary open angle glaucoma. Clin. Ophthalmol. 5 (2011), 553–556.
17. Barcelona, P.F., Saragovi, H.U., A pro-nerve growth factor (proNGF) and NGF binding protein, alpha2-macroglobulin, differentially regulates p75 and TrkA receptors and is relevant to neurodegeneration ex vivo and in vivo. Mol. Cell. Biol. 35 (2015), 3396–3408.
18. Bartus, R.T., Baumann, T.L., Siffert, J., Herzog, C.D., Alterman, R., Boulis, N., Turner, D.A., Stacy, M., Lang, A.E., Lozano, A.M., Olanow, C.W., Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80 (2013), 1698–1701.
19. Bekris, L.M., Yu, C.E., Bird, T.D., Tsuang, D.W., Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 23 (2010), 213–227.
20. Bikbova, G., Oshitari, T., Baba, T., Yamamoto, S., Neurotrophic factors for retinal ganglion cell neuropathy - with a special reference to diabetic neuropathy in the retina. Curr. Diabetes Rev. 10 (2014), 166–176.
21. Birch, D.G., Weleber, R.G., Duncan, J.L., Jaffe, G.J., Tao, W., Ciliary Neurotrophic Factor Retinitis Pigmentosa Study, G., Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J. Ophthalmol., 156(283–292), 2013, e281.
22. Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., Jackson-Lewis, V.R., Oxidative stress and Parkinson's disease. Front. Neuroanat., 9, 2015, 91.
23. Bobkova, N., Medvinskaya, N., Nesterova, I., Samokhin, A., Kamynina, A., Koroev, D., Volkova, T., Zaporozhskaya, Y., Volpina, O., Structure–function mapping of the extracellular part of neurotrophin receptor P75. Biochem. (Moscow) Suppl. Ser. A Membr. Cell Biol. 9 (2015), 185–193.
24. Bollen, E., Vanmierlo, T., Akkerman, S., Wouters, C., Steinbusch, H.M., Prickaerts, J., 7,8-dihydroxyflavone improves memory consolidation processes in rats and mice. Behav. Brain Res. 257 (2013), 8–12.
25. Bonini, S., Lambiase, A., Rama, P., Caprioglio, G., Aloe, L., Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 107 (2000), 1347–1351 (discussion 1351-1342).
26. Brantley, M.A. Jr., Jain, S., Barr, E.E., Johnson, E.M. Jr., Milbrandt, J., Neurturin-mediated ret activation is required for retinal function. J. Neurosci. 28 (2008), 4123–4135.
27. Brito, V., Giralt, A., Enriquez-Barreto, L., Puigdellivol, M., Suelves, N., Zamora-Moratalla, A., Ballesteros, J.J., Martin, E.D., Dominguez-Iturza, N., Morales, M., Alberch, J., Gines, S., Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction. J. Clin. Invest. 124 (2014), 4411–4428.
28. Bruno, M.A., Clarke, P.B., Seltzer, A., Quirion, R., Burgess, K., Cuello, A.C., Saragovi, H.U., Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J. Neurosci. 24 (2004), 8009–8018.
29. Burgess, A., Shah, K., Hough, O., Hynynen, K., Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert. Rev. Neurother. 15 (2015), 477–491.
30. Carmignoto, G., Maffei, L., Candeo, P., Canella, R., Comelli, C., Effect of NGF on the survival of rat retinal ganglion cells following optic nerve section. J. Neurosci. 9 (1989), 1263–1272.
31. Carroll, J.B., Bates, G.P., Steffan, J., Saft, C., Tabrizi, S.J., Treating the whole body in Huntington's disease. Lancet Neurol. 14 (2015), 1135–1142.
32. Cetin, H., Rath, J., Fuzi, J., Reichardt, B., Fulop, G., Koppi, S., Erdler, M., Ransmayr, G., Weber, J., Neumann, K., Hagmann, M., Loscher, W.N., Auff, E., Zimprich, F., Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. Neuroepidemiology 44 (2015), 6–15.
33. Chadwick, W., Mitchell, N., Caroll, J., Zhou, Y., Park, S.S., Wang, L., Becker, K.G., Zhang, Y., Lehrmann, E., Wood, W.H. 3rd, Martin, B., Maudsley, S., Amitriptyline-mediated cognitive enhancement in aged 3 × Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PLoS One, 6, 2011, e21660.
34. Chakravarthy, B., Gaudet, C., Menard, M., Atkinson, T., Brown, L., Laferla, F.M., Armato, U., Whitfield, J., Amyloid-beta peptides stimulate the expression of the p75(NTR) neurotrophin receptor in SHSY5Y human neuroblastoma cells and AD transgenic mice. J. Alzheimers Dis. 19 (2010), 915–925.
35. Chakravarty, S., Maitra, S., Reddy, R.G., Das, T., Jhelum, P., Kootar, S., Rajan, W.D., Samanta, A., Samineni, R., Pabbaraja, S., Kernie, S.G., Mehta, G., Kumar, A., A novel natural product inspired scaffold with robust neurotrophic, neurogenic and neuroprotective action. Sci. Rep., 5, 2015, 14134.
36. Chang, E.J., Im, Y.S., Kay, E.P., Kim, J.Y., Lee, J.E., Lee, H.K., The role of nerve growth factor in hyperosmolar stress induced apoptosis. J. Cell. Physiol. 216 (2008), 69–77.
37. Charan, R.A., LaVoie, M.J., Pathologic and therapeutic implications for the cell biology of parkin. Mol. Cell. Neurosci. 66 (2015), 62–71.
38. Chatterjee, S., Mizar, P., Cassel, R., Neidl, R., Selvi, B.R., Mohankrishna, D.V., Vedamurthy, B.M., Schneider, A., Bousiges, O., Mathis, C., Cassel, J.C., Eswaramoorthy, M., Kundu, T.K., Boutillier, A.L., A novel activator of CBP/p300 acetyltransferases promotes neurogenesis and extends memory duration in adult mice. J. Neurosci. 33 (2013), 10698–10712.
39. Checa-Casalengua, P., Jiang, C., Bravo-Osuna, I., Tucker, B.A., Molina-Martinez, I.T., Young, M.J., Herrero-Vanrell, R., Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J. Control. Release 156 (2011), 92–100.
40. Chen, L., Yung, K., Chan, Y., Shum, D., Bolam, J., The proNGF-p75NTR-sortilin signalling complex as new target for the therapeutic treatment of Parkinson's disease. CNS Neurol. Disord. Drug Targets 7 (2008), 512–523.
41. Chen, J., Chua, K.W., Chua, C.C., Yu, H., Pei, A., Chua, B.H., Hamdy, R.C., Xu, X., Liu, C.F., Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity. Neurosci. Lett. 499 (2011), 181–185.
42. Chen, Z., Chen, B., Xu, W.F., Liu, R.F., Yang, J., Yu, C.X., Effects of PTEN inhibition on regulation of tau phosphorylation in an okadaic acid-induced neurodegeneration model. Int. J. Dev. Neurosci. 30 (2012), 411–419.
43. Chitranshi, N., Gupta, V., Kumar, S., Graham, S.L., Exploring the molecular interactions of 7,8-dihydroxyflavone and its derivatives with TrkB and VEGFR2 proteins. Int. J. Mol. Sci. 16 (2015), 21087–21108.
44. Chong, N.H., Alexander, R.A., Waters, L., Barnett, K.C., Bird, A.C., Luthert, P.J., Repeated injections of a ciliary neurotrophic factor analogue leading to long-term photoreceptor survival in hereditary retinal degeneration. Invest. Ophthalmol. Vis. Sci. 40 (1999), 1298–1305.
45. Chou, S.Y., Lee, Y.C., Chen, H.M., Chiang, M.C., Lai, H.L., Chang, H.H., Wu, Y.C., Sun, C.N., Chien, C.L., Lin, Y.S., Wang, S.C., Tung, Y.Y., Chang, C., Chern, Y., CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93 (2005), 310–320.
46. Cong, W.N., Chadwick, W., Wang, R., Daimon, C.M., Cai, H., Amma, J., Wood, W.H. 3rd, Becker, K.G., Martin, B., Maudsley, S., Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model. J. Biol. Chem. 290 (2015), 2728–2743.
47. Counts, S.E., Nadeem, M., Wuu, J., Ginsberg, S.D., Saragovi, H.U., Mufson, E.J., Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann. Neurol. 56 (2004), 520–531.
48. Croll, S.D., Ip, N.Y., Lindsay, R.M., Wiegand, S.J., Expression of BDNF and trkB as a function of age and cognitive performance. Brain Res. 812 (1998), 200–208.
49. Crook, T.H., Ferris, S.H., Alvarez, X.A., Laredo, M., Moessler, H., Effects of N-PEP-12 on memory among older adults. Int. Clin. Psychopharmacol. 20 (2005), 97–100.
50. Cuello, A.C., Bruno, M.A., The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Neurochem. Res. 32 (2007), 1041–1045.
51. Cuello, A.C., Bruno, M.A., Allard, S., Leon, W., Iulita, M.F., Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J. Mol. Neurosci. 40 (2010), 230–235.
52. Cuenca, N., Fernandez-Sanchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., Pinilla, I., Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog. Retin. Eye Res. 43 (2014), 17–75.
53. Dalkara, D., Kolstad, K.D., Guerin, K.I., Hoffmann, N.V., Visel, M., Klimczak, R.R., Schaffer, D.V., Flannery, J.G., AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. Mol. Ther. 19 (2011), 1602–1608.
54. Dechant, G., Barde, Y.A., The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat. Neurosci. 5 (2002), 1131–1136.
55. Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., Singleton, A., Olanow, C.W., Merchant, K.M., Bezard, E., Petsko, G.A., Meissner, W.G., Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 14 (2015), 855–866.
56. Del Rio, P., Irmler, M., Arango-Gonzalez, B., Favor, J., Bobe, C., Bartsch, U., Vecino, E., Beckers, J., Hauck, S.M., Ueffing, M., GDNF-induced osteopontin from Muller glial cells promotes photoreceptor survival in the Pde6brd1 mouse model of retinal degeneration. Glia 59 (2011), 821–832.
57. Delyfer, M.N., Simonutti, M., Neveux, N., Leveillard, T., Sahel, J.A., Does GDNF exert its neuroprotective effects on photoreceptors in the rd1 retina through the glial glutamate transporter GLAST?. Mol. Vis. 11 (2005), 677–687.
58. Dennys, C.N., Armstrong, J., Levy, M., Byun, Y.J., Ramdial, K.R., Bott, M., Rossi, F.H., Fernandez-Valle, C., Franco, M.C., Estevez, A.G., Chronic inhibitory effect of riluzole on trophic factor production. Exp. Neurol. 271 (2015), 301–307.
59. Devi, L., Ohno, M., 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology 37 (2012), 434–444.
60. Di Girolamo, N., Sarris, M., Chui, J., Cheema, H., Coroneo, M.T., Wakefield, D., Localization of the low-affinity nerve growth factor receptor p75 in human limbal epithelial cells. J. Cell. Mol. Med. 12 (2008), 2799–2811.
61. Di Polo, A., Aigner, L.J., Dunn, R.J., Bray, G.M., Aguayo, A.J., Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 3978–3983.
62. Domenici, L., Origlia, N., Falsini, B., Cerri, E., Barloscio, D., Fabiani, C., Sanso, M., Giovannini, L., Rescue of retinal function by BDNF in a mouse model of glaucoma. PLoS One, 9, 2014, e115579.
63. Domeniconi, M., Chao, M.V., Transactivation of Trk receptors in spinal motor neurons. Histol. Histopathol. 25 (2010), 1207–1213.
64. Doonan, F., O'Driscoll, C., Kenna, P., Cotter, T.G., Enhancing survival of photoreceptor cells in vivo using the synthetic progestin Norgestrel. J. Neurochem. 118 (2011), 915–927.
65. Dorsey, S.G., Renn, C.L., Carim-Todd, L., Barrick, C.A., Bambrick, L., Krueger, B.K., Ward, C.W., Tessarollo, L., In vivo restoration of physiological levels of truncated TrkB.T1 receptor rescues neuronal cell death in a trisomic mouse model. Neuron 51 (2006), 21–28.
66. Dorsey, S.G., Lovering, R.M., Renn, C.L., Leitch, C.C., Liu, X., Tallon, L.J., Sadzewicz, L.D., Pratap, A., Ott, S., Sengamalay, N., Jones, K.M., Barrick, C., Fulgenzi, G., Becker, J., Voelker, K., Talmadge, R., Harvey, B.K., Wyatt, R.M., Vernon-Pitts, E., Zhang, C., Shokat, K., Fraser-Liggett, C., Balice-Gordon, R.J., Tessarollo, L., Ward, C.W., Genetic deletion of trkB.T1 increases neuromuscular function. Am. J. Physiol. Cell Physiol. 302 (2012), C141–C153.
67. Drachman, D.A., The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement. 10 (2014), 372–380.
68. Duong, F., Fournier, J., Keane, P.E., Guenet, J.L., Soubrie, P., Warter, J.M., Borg, J., Poindron, P., The effect of the nonpeptide neurotrophic compound SR 57746A on the progression of the disease state of the pmn mouse. Br. J. Pharmacol. 124 (1998), 811–817.
69. Ekestern, E., Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener. Dis. 1 (2004), 88–100.
70. Elliott, J.L., Snider, W.D., Motor neuron growth factors. Neurology 47 (1996), S47–S53.
71. Emerich, D.F., Orive, G., Thanos, C., Tornoe, J., Wahlberg, L.U., Encapsulated cell therapy for neurodegenerative diseases: from promise to product. Adv. Drug Deliv. Rev. 67-68 (2014), 131–141.
72. Eriksdotter Jonhagen, M., Nordberg, A., Amberla, K., Backman, L., Ebendal, T., Meyerson, B., Olson, L., Seiger, S.M., Theodorsson, E., Viitanen, M., Winblad, B., Wahlund, L.O., Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9 (1998), 246–257.
73. Fernandez Lopez, E., Karaca, E.E., Ekici, F., Waisbourd, M., Spaeth, G.L., Symptoms reported by patients with varying stages of glaucoma: review of 401 cases. Can. J. Ophthalmol. 49 (2014), 420–425.
74. Ferrer, I., Marin, C., Rey, M.J., Ribalta, T., Goutan, E., Blanco, R., Tolosa, E., Marti, E., BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol. 58 (1999), 729–739.
75. Fombonne, J., Rabizadeh, S., Banwait, S., Mehlen, P., Bredesen, D.E., Selective vulnerability in Alzheimer's disease: amyloid precursor protein and p75(NTR) interaction. Ann. Neurol. 65 (2009), 294–303.
76. Frade, J.M., Rodriguez-Tebar, A., Barde, Y.A., Induction of cell death by endogenous nerve growth factor through its p75 receptor. Nature 383 (1996), 166–168.
77. Frasson, M., Picaud, S., Leveillard, T., Simonutti, M., Mohand-Said, S., Dreyfus, H., Hicks, D., Sabel, J., Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse. Invest. Ophthalmol. Vis. Sci. 40 (1999), 2724–2734.
78. Gao, H., Qiao, X., Cantor, L.B., WuDunn, D., Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch. Ophthalmol. 120 (2002), 797–803.
79. Gauthier, L.R., Charrin, B.C., Borrell-Pages, M., Dompierre, J.P., Rangone, H., Cordelieres, F.P., De Mey, J., MacDonald, M.E., Lessmann, V., Humbert, S., Saudou, F., Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118 (2004), 127–138.
80. Gayton, J.L., Etiology, prevalence, and treatment of dry eye disease. Clin. Ophthalmol. 3 (2009), 405–412.
81. Gevaert, B., D'Hondt, M., Bracke, N., Yao, H., Wynendaele, E., Vissers, J.P., De Cecco, M., Claereboudt, J., De Spiegeleer, B., Peptide profiling of Internet-obtained cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry. Drug Test. Anal. 7 (2015), 835–842.
82. Gimenez, F., Krauze, M.T., Valles, F., Hadaczek, P., Bringas, J., Sharma, N., Forsayeth, J., Bankiewicz, K.S., Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. NeuroImage 54:Suppl 1 (2011), S189–S195.
83. Gipson, I.K., The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture. Invest. Ophthalmol. Vis. Sci., 48, 2007, 4390 (4391-4398).
84. Goldberg, N.R., Caesar, J., Park, A., Sedgh, S., Finogenov, G., Masliah, E., Davis, J., Blurton-Jones, M., Neural stem cells rescue cognitive and motor dysfunction in a transgenic model of dementia with Lewy bodies through a BDNF-dependent mechanism. Stem Cell Rep. 5 (2015), 791–804.
85. Gregory-Evans, K., Chang, F., Hodges, M.D., Gregory-Evans, C.Y., Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol. Vis. 15 (2009), 962–973.
86. Guadagni, V., Novelli, E., Piano, I., Gargini, C., Strettoi, E., Pharmacological approaches to retinitis pigmentosa: a laboratory perspective. Prog. Retin. Eye Res. 48 (2015), 62–81.
87. Gupta, V.K., You, Y., Gupta, V.B., Klistorner, A., Graham, S.L., TrkB receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. Int. J. Mol. Sci. 14 (2013), 10122–10142.
88. Gupta, V.K., You, Y., Li, J.C., Klistorner, A., Graham, S.L., Protective effects of 7,8-dihydroxyflavone on retinal ganglion and RGC-5 cells against excitotoxic and oxidative stress. J. Mol. Neurosci. 49 (2013), 96–104.
89. Gutzmann, H., Hadler, D., Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J. Neural Transm. Suppl. 54 (1998), 301–310.
90. Han, X., Zhu, S., Wang, B., Chen, L., Li, R., Yao, W., Qu, Z., Antioxidant action of 7,8-dihydroxyflavone protects PC12 cells against 6-hydroxydopamine-induced cytotoxicity. Neurochem. Int. 64 (2014), 18–23.
91. Hauck, S.M., Kinkl, N., Deeg, C.A., Swiatek-de Lange, M., Schoffmann, S., Ueffing, M., GDNF family ligands trigger indirect neuroprotective signaling in retinal glial cells. Mol. Cell. Biol. 26 (2006), 2746–2757.
92. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nat. Biotechnol. 32 (2014), 40–51.
93. He, X.L., Garcia, K.C., Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science 304 (2004), 870–875.
94. Hedstrom, K.L., Murtie, J.C., Albers, K., Calcutt, N.A., Corfas, G., Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFRalpha/RET receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 2325–2330.
95. Hu, X.Y., Zhang, H.Y., Qin, S., Xu, H., Swaab, D.F., Zhou, J.N., Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients. Exp. Neurol. 178 (2002), 104–111.
96. Huang, E.J., Reichardt, L.F., Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 72 (2003), 609–642.
97. Huang, H., Gandhi, J.K., Zhong, X., Wei, Y., Gong, J., Duh, E.J., Vinores, S.A., TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest. Ophthalmol. Vis. Sci. 52 (2011), 1336–1344.
98. Huang, J., Chu, Z., Chen, L., Wang, Y., Zhang, L., Hu, Y., Sun, C., Effect of shRNA-mediated silencing of BDNF gene on VEGF expression of RPMI8226 cells. Zhonghua Xue Ye Xue Za Zhi 36 (2015), 403–407.
99. Hughes, S.R., Khorkova, O., Goyal, S., Knaeblein, J., Heroux, J., Riedel, N.G., Sahasrabudhe, S., Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 3275–3280.
100. Ibanez, C.F., Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb. Perspect. Biol., 5, 2013.
101. Igarashi, Y., Chiba, H., Utsumi, H., Miyajima, H., Ishizaki, T., Gotoh, T., Kuwahara, K., Tobioka, H., Satoh, M., Mori, M., Sawada, N., Expression of receptors for glial cell line-derived neurotrophic factor (GDNF) and neurturin in the inner blood-retinal barrier of rats. Cell Struct. Funct. 25 (2000), 237–241.
102. Jaeger, S., Pietrzik, C.U., Functional role of lipoprotein receptors in Alzheimer's disease. Curr. Alzheimer Res. 5 (2008), 15–25.
103. Jain, P., Li, R., Lama, T., Saragovi, H.U., Cumberlidge, G., Meerovitch, K., An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Exp. Eye Res. 93 (2011), 503–512.
104. Jang, S.W., Okada, M., Sayeed, I., Xiao, G., Stein, D., Jin, P., Ye, K., Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 16329–16334.
105. Jang, S.W., Liu, X., Chan, C.B., Weinshenker, D., Hall, R.A., Xiao, G., Ye, K., Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem. Biol. 16 (2009), 644–656.
106. Jang, S.W., Liu, X., Chan, C.B., France, S.A., Sayeed, I., Tang, W., Lin, X., Xiao, G., Andero, R., Chang, Q., Ressler, K.J., Ye, K., Deoxygedunin, a natural product with potent neurotrophic activity in mice. PLoS One, 5, 2010, e11528.
107. Jang, S.W., Liu, X., Yepes, M., Shepherd, K.R., Miller, G.W., Liu, Y., Wilson, W.D., Xiao, G., Blanchi, B., Sun, Y.E., Ye, K., A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 2687–2692.
108. Jiang, C., Moore, M.J., Zhang, X., Klassen, H., Langer, R., Young, M., Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol. Vis. 13 (2007), 1783–1792.
109. Jiang, M., Peng, Q., Liu, X., Jin, J., Hou, Z., Zhang, J., Mori, S., Ross, C.A., Ye, K., Duan, W., Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum. Mol. Genet. 22 (2013), 2462–2470.
110. Jomary, C., Thomas, M., Grist, J., Milbrandt, J., Neal, M.J., Jones, S.E., Expression patterns of neurturin and its receptor components in developing and degenerative mouse retina. Invest. Ophthalmol. Vis. Sci. 40 (1999), 568–574.
111. Joussen, A.M., Doehmen, S., Le, M.L., Koizumi, K., Radetzky, S., Krohne, T.U., Poulaki, V., Semkova, I., Kociok, N., TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 15 (2009), 1418–1428.
112. Kalia, L.V., Kalia, S.K., Lang, A.E., Disease-modifying strategies for Parkinson's disease. Mov. Disord. 30 (2015), 1442–1450.
113. Kawasumi, M., Hashimoto, Y., Chiba, T., Kanekura, K., Yamagishi, Y., Ishizaka, M., Tajima, H., Niikura, T., Nishimoto, I., Molecular mechanisms for neuronal cell death by Alzheimer's amyloid precursor protein-relevant insults. Neurosignals 11 (2002), 236–250.
114. Knowles, J.K., Simmons, D.A., Nguyen, T.V., Vander Griend, L., Xie, Y., Zhang, H., Yang, T., Pollak, J., Chang, T., Arancio, O., Buckwalter, M.S., Wyss-Coray, T., Massa, S.M., Longo, F.M., Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. Neurobiol. Aging 34 (2013), 2052–2063.
115. Kordower, J.H., Chen, E.Y., Sladek, J.R. Jr., Mufson, E.J., Trk-immunoreactivity in the monkey central nervous system: forebrain. J. Comp. Neurol. 349 (1994), 20–35.
116. Korkmaz, O.T., Aytan, N., Carreras, I., Choi, J.K., Kowall, N.W., Jenkins, B.G., Dedeoglu, A., 7,8-dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 566 (2014), 286–291.
117. Kruttgen, A., Saxena, S., Evangelopoulos, M.E., Weis, J., Neurotrophins and neurodegenerative diseases: receptors stuck in traffic?. J. Neuropathol. Exp. Neurol. 62 (2003), 340–350.
118. Lambiase, A., Manni, L., Bonini, S., Rama, P., Micera, A., Aloe, L., Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest. Ophthalmol. Vis. Sci. 41 (2000), 1063–1069.
119. Lambiase, A., Mantelli, F., Bonini, S., Nerve growth factor eye drops to treat glaucoma. Drug News Perspect. 23 (2010), 361–367.
120. Lambiase, A., Micera, A., Sacchetti, M., Cortes, M., Mantelli, F., Bonini, S., Alterations of tear neuromediators in dry eye disease. Arch. Ophthalmol. 129 (2011), 981–986.
121. Lang, A.E., Gill, S., Patel, N.K., Lozano, A., Nutt, J.G., Penn, R., Brooks, D.J., Hotton, G., Moro, E., Heywood, P., Brodsky, M.A., Burchiel, K., Kelly, P., Dalvi, A., Scott, B., Stacy, M., Turner, D., Wooten, V.G., Elias, W.J., Laws, E.R., Dhawan, V., Stoessl, A.J., Matcham, J., Coffey, R.J., Traub, M., Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59 (2006), 459–466.
122. LaVail, M.M., Unoki, K., Yasumura, D., Matthes, M.T., Yancopoulos, G.D., Steinberg, R.H., Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc. Natl. Acad. Sci. U. S. A. 89 (1992), 11249–11253.
123. Le, A.P., Friedman, W.J., Matrix metalloproteinase-7 regulates cleavage of pro-nerve growth factor and is neuroprotective following kainic acid-induced seizures. J. Neurosci. 32 (2012), 703–712.
124. Lebrun-Julien, F., Morquette, B., Douillette, A., Saragovi, H.U., Di Polo, A., Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Mol. Cell. Neurosci. 40 (2009), 410–420.
125. Lebrun-Julien, F., Bertrand, M.J., De Backer, O., Stellwagen, D., Morales, C.R., Di Polo, A., Barker, P.A., ProNGF induces TNFalpha-dependent death of retinal ganglion cells through a p75NTR non-cell-autonomous signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 3817–3822.
126. Lee, E.S., Flannery, J.G., Transport of truncated rhodopsin and its effects on rod function and degeneration. Invest. Ophthalmol. Vis. Sci. 48 (2007), 2868–2876.
127. Lee, H.K., Lee, K.S., Kim, H.C., Lee, S.H., Kim, E.K., Nerve growth factor concentration and implications in photorefractive keratectomy vs laser in situ keratomileusis. Am J. Ophthalmol. 139 (2005), 965–971.
128. Lemaire, L., Fournier, J., Ponthus, C., Le Fur, Y., Confort-Gouny, S., Vion-Dury, J., Keane, P., Cozzone, P.J., Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats. Investig. Radiol. 37 (2002), 321–327.
129. Li, W., Sun, X., Wang, Z., Li, R., Li, L., The effect of nerve growth factor on differentiation of corneal limbal epithelial cells to conjunctival goblet cells in vitro. Mol. Vis. 16 (2010), 2739–2744.
130. Lindqvist, N., Peinado-Ramonn, P., Vidal-Sanz, M., Hallbook, F., GDNF, Ret, GFRalpha1 and 2 in the adult rat retino-tectal system after optic nerve transection. Exp. Neurol. 187 (2004), 487–499.
131. Liot, G., Zala, D., Pla, P., Mottet, G., Piel, M., Saudou, F., Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J. Neurosci. 33 (2013), 6298–6309.
132. Lipinski, D.M., Barnard, A.R., Singh, M.S., Martin, C., Lee, E.J., Davies, W.I., MacLaren, R.E., CNTF Gene therapy confers lifelong neuroprotection in a mouse model of human retinitis pigmentosa. Mol. Ther. 23 (2015), 1308–1319.
133. Liu, X., Chan, C.B., Jang, S.W., Pradoldej, S., Huang, J., He, K., Phun, L.H., France, S., Xiao, G., Jia, Y., Luo, H.R., Ye, K., A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect. J. Med. Chem. 53 (2010), 8274–8286.
134. Liu, X., Chan, C.B., Qi, Q., Xiao, G., Luo, H.R., He, X., Ye, K., Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression. J. Med. Chem. 55 (2012), 8524–8537.
135. Liu, Y., Tao, L., Fu, X., Zhao, Y., Xu, X., BDNF protects retinal neurons from hyperglycemia through the TrkB/ERK/MAPK pathway. Mol. Med. Rep. 7 (2013), 1773–1778.
136. Liu-Seifert, H., Andersen, S., Holdridge, K., Siemers, E., Delayed-start analyses of solanezumab phase 3 studies in mild Alzheimer's disease (P7. 108). Neurology, 84, 2015 (P7. 108).
137. Love, S., Plaha, P., Patel, N.K., Hotton, G.R., Brooks, D.J., Gill, S.S., Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med. 11 (2005), 703–704.
138. Ma, K., Yan, N., Huang, Y., Cao, G., Deng, J., Deng, Y., Effects of nerve growth factor on nerve regeneration after corneal nerve damage. Int. J. Clin. Exp. Med. 7 (2014), 4584–4589.
139. Maliartchouk, S., Saragovi, H.U., Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands. J. Neurosci. 17 (1997), 6031–6037.
140. Maliartchouk, S., Feng, Y., Ivanisevic, L., Debeir, T., Cuello, A.C., Burgess, K., Saragovi, H.U., A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol. Pharmacol. 57 (2000), 385–391.
141. Mangan, B.G., Al-Yahya, K., Chen, C.T., Gionfriddo, J.R., Powell, C.C., Dubielzig, R.R., Ehrhart, E.J., Madl, J.E., Retinal pigment epithelial damage, breakdown of the blood-retinal barrier, and retinal inflammation in dogs with primary glaucoma. Vet. Ophthalmol. 10:Suppl 1 (2007), 117–124.
142. Mansour-Robaey, S., Clarke, D.B., Wang, Y.C., Bray, G.M., Aguayo, A.J., Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 1632–1636.
143. Marks, W.J. Jr., Ostrem, J.L., Verhagen, L., Starr, P.A., Larson, P.S., Bakay, R.A., Taylor, R., Cahn-Weiner, D.A., Stoessl, A.J., Olanow, C.W., Bartus, R.T., Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7 (2008), 400–408.
144. Marks, W.J. Jr., Bartus, R.T., Siffert, J., Davis, C.S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., Bakay, R., Watts, R., Guthrie, B., Jankovic, J., Simpson, R., Tagliati, M., Alterman, R., Stern, M., Baltuch, G., Starr, P.A., Larson, P.S., Ostrem, J.L., Nutt, J., Kieburtz, K., Kordower, J.H., Olanow, C.W., Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9 (2010), 1164–1172.
145. Masoudi, R., Ioannou, M.S., Coughlin, M.D., Pagadala, P., Neet, K.E., Clewes, O., Allen, S.J., Dawbarn, D., Fahnestock, M., Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. J. Biol. Chem. 284 (2009), 18424–18433.
146. Massa, S.M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J.N., Nehama, D., Rajadas, J., Longo, F.M., Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Invest. 120 (2010), 1774–1785.
147. Meerovitch, K., Torkildsen, G., Lonsdale, J., Goldfarb, H., Lama, T., Cumberlidge, G., Ousler, G.W. 3rd, Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled phase 2 clinical trial in patients with dry eye. Clin. Ophthalmol. 7 (2013), 1275–1285.
148. Meerovitch, K., Brazzell, K., Ousler, G.W., Cumberlidge, G., Improvements in signs and symptoms of dry eye with MIM-D3 1% ophthalmic solution compared to placebo in different patient populations. Invest. Ophthalmol. Vis. Sci., 56, 2015, 4460.
149. Meininger, V., Bensimon, G., Bradley, W.R., Brooks, B., Douillet, P., Eisen, A.A., Lacomblez, L., Leigh, P.N., Robberecht, W., Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5 (2004), 107–117.
150. Mi, X.S., Yuan, T.F., So, K.F., The current research status of normal tension glaucoma. Clin. Interv. Aging 9 (2014), 1563–1571.
151. Micera, A., Lambiase, A., Puxeddu, I., Aloe, L., Stampachiacchiere, B., Levi-Schaffer, F., Bonini, S., Bonini, S., Nerve growth factor effect on human primary fibroblastic-keratocytes: possible mechanism during corneal healing. Exp. Eye Res. 83 (2006), 747–757.
152. Michaelsen, K., Zagrebelsky, M., Berndt-Huch, J., Polack, M., Buschler, A., Sendtner, M., Korte, M., Neurotrophin receptors TrkB.T1 and p75NTR cooperate in modulating both functional and structural plasticity in mature hippocampal neurons. Eur. J. Neurosci. 32 (2010), 1854–1865.
153. Miller, F.D., Kaplan, D.R., On trk for retrograde signaling. Neuron 32 (2001), 767–770.
154. Mitchell, J.D., Borasio, G.D., Amyotrophic lateral sclerosis. Lancet 369 (2007), 2031–2041.
155. Mocchetti, I., Brown, M., Targeting neurotrophin receptors in the central nervous system. CNS Neurol. Disord. Drug Targets 7 (2008), 71–82.
156. Mufson, E.J., Conner, J.M., Kordower, J.H., Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport 6 (1995), 1063–1066.
157. Mufson, E.J., Lavine, N., Jaffar, S., Kordower, J.H., Quirion, R., Saragovi, H.U., Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp. Neurol. 146 (1997), 91–103.
158. Mufson, E.J., Ma, S.Y., Cochran, E.J., Bennett, D.A., Beckett, L.A., Jaffar, S., Saragovi, H.U., Kordower, J.H., Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol. 427 (2000), 19–30.
159. Muller, M., Triaca, V., Besusso, D., Costanzi, M., Horn, J.M., Koudelka, J., Geibel, M., Cestari, V., Minichiello, L., Loss of NGF-TrkA signaling from the CNS is not sufficient to induce cognitive impairments in young adult or intermediate-aged mice. J. Neurosci. 32 (2012), 14885–14898.
160. Mutoh, T., Sobue, G., Hamano, T., Kuriyama, M., Hirayama, M., Yamamoto, M., Mitsuma, T., Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. Neurochem. Res. 25 (2000), 239–245.
161. Mysona, B.A., Al-Gayyar, M.M., Matragoon, S., Abdelsaid, M.A., El-Azab, M.F., Saragovi, H.U., El-Remessy, A.B., Modulation of p75(NTR) prevents diabetes- and proNGF-induced retinal inflammation and blood-retina barrier breakdown in mice and rats. Diabetologia 56 (2013), 2329–2339.
162. Mysona, B.A., Matragoon, S., Stephens, M., Mohamed, I.N., Farooq, A., Bartasis, M.L., Fouda, A.Y., Shanab, A.Y., Espinosa-Heidmann, D.G., El-Remessy, A.B., Imbalance of the nerve growth factor and its precursor as a potential biomarker for diabetic retinopathy. BioMed Res. Int., 2015, 2015, 571456.
163. Nafissi, N., Foldvari, M., Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8 (2016), 240–254.
164. Nagahara, A.H., Merrill, D.A., Coppola, G., Tsukada, S., Schroeder, B.E., Shaked, G.M., Wang, L., Blesch, A., Kim, A., Conner, J.M., Rockenstein, E., Chao, M.V., Koo, E.H., Geschwind, D., Masliah, E., Chiba, A.A., Tuszynski, M.H., Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15 (2009), 331–337.
165. Nguyen, T.V., Shen, L., Vander Griend, L., Quach, L.N., Belichenko, N.P., Saw, N., Yang, T., Shamloo, M., Wyss-Coray, T., Massa, S.M., Longo, F.M., Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AbetaPP(L/S) transgenic mice. J. Alzheimers Dis. 42 (2014), 459–483.
166. Nickells, R.W., Howell, G.R., Soto, I., John, S.W., Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu. Rev. Neurosci. 35 (2012), 153–179.
167. Nie, S., Xu, Y., Chen, G., Ma, K., Han, C., Guo, Z., Zhang, Z., Ye, K., Cao, X., Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents. Neuropharmacology 99 (2015), 448–458.
168. Nishikiori, N., Osanai, M., Chiba, H., Kojima, T., Mitamura, Y., Ohguro, H., Sawada, N., Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Diabetes 56 (2007), 1333–1340.
169. Nykjaer, A., Willnow, T.E., Petersen, C.M., p75NTR–live or let die. Curr. Opin. Neurobiol. 15 (2005), 49–57.
170. Obianyo, O., Ye, K., Novel small molecule activators of the Trk family of receptor tyrosine kinases. Biochim. Biophys. Acta 1834 (2013), 2213–2218.
171. Ochs, G., Penn, R.D., York, M., Giess, R., Beck, M., Tonn, J., Haigh, J., Malta, E., Traub, M., Sendtner, M., Toyka, K.V., A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1 (2000), 201–206.
172. Ohnaka, M., Miki, K., Gong, Y.Y., Stevens, R., Iwase, T., Hackett, S.F., Campochiaro, P.A., Long-term expression of glial cell line-derived neurotrophic factor slows, but does not stop retinal degeneration in a model of retinitis pigmentosa. J. Neurochem. 122 (2012), 1047–1053.
173. Ola, M.S., Nawaz, M.I., El-Asrar, A.A., Abouammoh, M., Alhomida, A.S., Reduced levels of brain derived neurotrophic factor (BDNF) in the serum of diabetic retinopathy patients and in the retina of diabetic rats. Cell. Mol. Neurobiol. 33 (2013), 359–367.
174. Ola, M.S., Ahmed, M.M., Ahmad, R., Abuohashish, H.M., Al-Rejaie, S.S., Alhomida, A.S., Neuroprotective effects of Rutin in streptozotocin-induced diabetic rat retina. J. Mol. Neurosci. 56 (2015), 440–448.
175. Orsini, M., Oliveira, A.B., Nascimento, O.J., Reis, C.H., Leite, M.A., de Souza, J.A., Pupe, C., de Souza, O.G., Bastos, V.H., de Freitas, M.R., Teixeira, S., Bruno, C., Davidovich, E., Smidt, B., Amyotrophic lateral sclerosis: new perspectives and update. Neurol. Int., 7, 2015, 5885.
176. Orsucci, D., Mancuso, M., Ienco, E.C., LoGerfo, A., Siciliano, G., Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr. Med. Chem. 18 (2011), 4053–4064.
177. Pardridge, W.M., Neurotrophins, neuroprotection and the blood-brain barrier. Curr. Opin. Investig. Drugs 3 (2002), 1753–1757.
178. Patel, N.K., Bunnage, M., Plaha, P., Svendsen, C.N., Heywood, P., Gill, S.S., Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 57 (2005), 298–302.
179. Pease, M.E., McKinnon, S.J., Quigley, H.A., Kerrigan-Baumrind, L.A., Zack, D.J., Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 41 (2000), 764–774.
180. Peleshok, J., Saragovi, H.U., Functional mimetics of neurotrophins and their receptors. Biochem. Soc. Trans. 34 (2006), 612–617.
181. Peng, S., Wuu, J., Mufson, E.J., Fahnestock, M., Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J. Neuropathol. Exp. Neurol. 63 (2004), 641–649.
182. Pinyon, J.L., Tadros, S.F., Froud, K.E., AC, Y.W., Tompson, I.T., Crawford, E.N., Ko, M., Morris, R., Klugmann, M., Housley, G.D., Close-field electroporation gene delivery using the cochlear implant electrode array enhances the bionic ear. Sci. Transl. Med., 6, 2014, 233ra254.
183. Plotkin, J.L., Day, M., Peterson, J.D., Xie, Z., Kress, G.J., Rafalovich, I., Kondapalli, J., Gertler, T.S., Flajolet, M., Greengard, P., Stavarache, M., Kaplitt, M.G., Rosinski, J., Chan, C.S., Surmeier, D.J., Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron 83 (2014), 178–188.
184. Porzner, M., Muller, T., Seufferlein, T., SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases. Expert Opin. Invest. Drugs 18 (2009), 1765–1772.
185. Pringsheim, T., Wiltshire, K., Day, L., Dykeman, J., Steeves, T., Jette, N., The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Movement Disord. 27 (2012), 1083–1091.
186. Pringsheim, T., Jette, N., Frolkis, A., Steeves, T.D., The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 29 (2014), 1583–1590.
187. Qi, H., Chuang, E.Y., Yoon, K.C., de Paiva, C.S., Shine, H.D., Jones, D.B., Pflugfelder, S.C., Li, D.Q., Patterned expression of neurotrophic factors and receptors in human limbal and corneal regions. Mol. Vis. 13 (2007), 1934–1941.
188. Quigley, H., Anderson, D.R., The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve. Investig. Ophthalmol. 15 (1976), 606–616.
189. Rafii, M.S., Baumann, T.L., Bakay, R.A., Ostrove, J.M., Siffert, J., Fleisher, A.S., Herzog, C.D., Barba, D., Pay, M., Salmon, D.P., Chu, Y., Kordower, J.H., Bishop, K., Keator, D., Potkin, S., Bartus, R.T., A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 10 (2014), 571–581.
190. Rangasamy, S.B., Soderstrom, K., Bakay, R.A., Kordower, J.H., Neurotrophic factor therapy for Parkinson's disease. Prog. Brain Res. 184 (2010), 237–264.
191. Reichardt, L.F., Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 361 (2006), 1545–1564.
192. Rhee, K.D., Nusinowitz, S., Chao, K., Yu, F., Bok, D., Yang, X.J., CNTF-mediated protection of photoreceptors requires initial activation of the cytokine receptor gp130 in Muller glial cells. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E4520–E4529.
193. Rolando, M., Zierhut, M., The ocular surface and tear film and their dysfunction in dry eye disease. Surv. Ophthalmol. 45:Suppl 2 (2001), S203–S210.
194. Roper, M.G., Qian, W.J., Zhang, B.B., Kulkarni, R.N., Kahn, C.R., Kennedy, R.T., Effect of the insulin mimetic L-783,281 on intracellular Ca2 + and insulin secretion from pancreatic beta-cells. Diabetes 51:Suppl 1 (2002), S43–S49.
195. Roux, P.P., Dorval, G., Boudreau, M., Angers-Loustau, A., Morris, S.J., Makkerh, J., Barker, P.A., K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J. Biol. Chem. 277 (2002), 49473–49480.
196. Ruberti, F., Capsoni, S., Comparini, A., Di Daniel, E., Franzot, J., Gonfloni, S., Rossi, G., Berardi, N., Cattaneo, A., Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J. Neurosci. 20 (2000), 2589–2601.
197. Rudzinski, M., Wong, T.P., Saragovi, H.U., Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J. Neurobiol. 58 (2004), 341–354.
198. Ruigt, G.S., Makkink, W.K., Konings, P.N., SR 57746A attenuates cytostatic drug-induced reduction of neurite outgrowth in co-cultures of rat dorsal root ganglia and Schwann cells. Neurosci. Lett. 203 (1996), 9–12.
199. Sabbagh, M.N., Drug development for Alzheimer's disease: where are we now and where are we headed?. Am. J. Geriatr. Pharmacother. 7 (2009), 167–185.
200. Sacchetti, M., Mantelli, F., Merlo, D., Lambiase, A., Systematic review of randomized clinical trials on safety and efficacy of pharmacological and nonpharmacological treatments for retinitis pigmentosa. J. Ophthalmol., 2015, 2015, 737053.
201. Salvatore, M.F., Ai, Y., Fischer, B., Zhang, A.M., Grondin, R.C., Zhang, Z., Gerhardt, G.A., Gash, D.M., Point source concentration of GDNF may explain failure of phase II clinical trial. Exp. Neurol. 202 (2006), 497–505.
202. Sanchez-Ortiz, E., Yui, D., Song, D., Li, Y., Rubenstein, J.L., Reichardt, L.F., Parada, L.F., TrkA gene ablation in basal forebrain results in dysfunction of the cholinergic circuitry. J. Neurosci. 32 (2012), 4065–4079.
203. Saragovi, H.U., Progression of age-associated cognitive impairment correlates with quantitative and qualitative loss of TrkA receptor protein in nucleus basalis and cortex. J. Neurochem. 95 (2005), 1472–1480.
204. Saragovi, H.U., Gehring, K., Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol. Sci. 21 (2000), 93–98.
205. Saragovi, H.U., Zaccaro, M.C., Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites. Curr. Pharm. Des. 8 (2002), 2201–2216.
206. Saragovi, H.U., Hamel, E., Di Polo, A., A neurotrophic rationale for the therapy of neurodegenerative disorders. Curr. Alzheimer Res. 6 (2009), 419–423.
207. Schindowski, K., Belarbi, K., Buee, L., Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 7:Suppl 1 (2008), 43–56.
208. Scott, S.A., Mufson, E.J., Weingartner, J.A., Skau, K.A., Crutcher, K.A., Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci. 15 (1995), 6213–6221.
209. Seki, M., Tanaka, T., Nawa, H., Usui, T., Fukuchi, T., Ikeda, K., Abe, H., Takei, N., Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53 (2004), 2412–2419.
210. Semba, K., Namekata, K., Kimura, A., Harada, C., Mitamura, Y., Harada, T., Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma. Cell Death Dis., 5, 2014, e1341.
211. Sendera, T.J., Ma, S.Y., Jaffar, S., Kozlowski, P.B., Kordower, J.H., Mawal, Y., Saragovi, H.U., Mufson, E.J., Reduction in TrkA-immunoreactive neurons is not associated with an overexpression of galaninergic fibers within the nucleus basalis in Down's syndrome. J. Neurochem. 74 (2000), 1185–1196.
212. Shah, C.P., Chen, C., Review of therapeutic advances in diabetic retinopathy. Ther. Adv. Endocrinol. Metab. 2 (2011), 39–53.
213. Shi, Z., Birman, E., Saragovi, H.U., Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Dev. Neurobiol. 67 (2007), 884–894.
214. Simmons, D.A., Belichenko, N.P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S.M., Longo, F.M., A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J. Neurosci. 33 (2013), 18712–18727.
215. Simmons, D.A., Knowles, J.K., Belichenko, N.P., Banerjee, G., Finkle, C., Massa, S.M., Longo, F.M., A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One, 9, 2014, e102136.
216. Skaper, S.D., The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol. Disord. Drug Targets 7 (2008), 46–62.
217. Skeldal, S., Sykes, A.M., Glerup, S., Matusica, D., Palstra, N., Autio, H., Boskovic, Z., Madsen, P., Castren, E., Nykjaer, A., Coulson, E.J., Mapping of the interaction site between sortilin and the p75 neurotrophin receptor reveals a regulatory role for the sortilin intracellular domain in p75 neurotrophin receptor shedding and apoptosis. J. Biol. Chem. 287 (2012), 43798–43809.
218. Slevin, J.T., Gash, D.M., Smith, C.D., Gerhardt, G.A., Kryscio, R., Chebrolu, H., Walton, A., Wagner, R., Young, A.B., Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg. 106 (2007), 614–620.
219. Squitieri, F., Orobello, S., Cannella, M., Martino, T., Romanelli, P., Giovacchini, G., Frati, L., Mansi, L., Ciarmiello, A., Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur. J. Nucl. Med. Mol. Imaging 36 (2009), 1113–1120.
220. Stephens, D.N., McNamara, N.A., Altered mucin and glycoprotein expression in dry eye disease. Optom. Vis. Sci. 92 (2015), 931–938.
221. Stewart, M.W., The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab. Syndr. Obes. 8 (2015), 473–482.
222. Stoilov, P., Castren, E., Stamm, S., Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem. Biophys. Res. Commun. 290 (2002), 1054–1065.
223. Tapley, P., Lamballe, F., Barbacid, M., K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene 7 (1992), 371–381.
224. Teng, K.K., Hempstead, B.L., Neurotrophins and their receptors: signaling trios in complex biological systems. Cell. Mol. Life Sci. 61 (2004), 35–48.
225. Tessarollo, L., Pleiotropic functions of neurotrophins in development. Cytokine Growth Factor Rev. 9 (1998), 125–137.
226. Thal, L.J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M.F., Zamrini, E., Thomas, R.G., Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 61 (2003), 1498–1502.
227. Tham, Y.C., Li, X., Wong, T.Y., Quigley, H.A., Aung, T., Cheng, C.Y., Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121 (2014), 2081–2090.
228. Thanos, C., Emerich, D., Delivery of neurotrophic factors and therapeutic proteins for retinal diseases. Expert. Opin. Biol. Ther. 5 (2005), 1443–1452.
229. The BDNF Study Group, A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF study group (phase III). Neurology 52 (1999), 1427–1433.
230. Todd, D., Gowers, I., Dowler, S.J., Wall, M.D., McAllister, G., Fischer, D.F., Dijkstra, S., Fratantoni, S.A., van de Bospoort, R., Veenman-Koepke, J., Flynn, G., Arjomand, J., Dominguez, C., Munoz-Sanjuan, I., Wityak, J., Bard, J.A., A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease. PLoS One, 9, 2014, e87923.
231. Tokugawa, K., Yamamoto, K., Nishiguchi, M., Sekine, T., Sakai, M., Ueki, T., Chaki, S., Okuyama, S., XIB4035, a novel nonpeptidyl small molecule agonist for GFRalpha-1. Neurochem. Int. 42 (2003), 81–86.
232. Touchard, E., Heiduschka, P., Berdugo, M., Kowalczuk, L., Bigey, P., Chahory, S., Gandolphe, C., Jeanny, J.C., Behar-Cohen, F., Non-viral gene therapy for GDNF production in RCS rat: the crucial role of the plasmid dose. Gene Ther. 19 (2012), 886–898.
233. Tsai, T., Klausmeyer, A., Conrad, R., Gottschling, C., Leo, M., Faissner, A., Wiese, S., 7,8-dihydroxyflavone leads to survival of cultured embryonic motoneurons by activating intracellular signaling pathways. Mol. Cell. Neurosci. 56 (2013), 18–28.
234. Tuszynski, M.H., Yang, J.H., Barba, D., U, H.S., Bakay, R.A., Pay, M.M., Masliah, E., Conner, J.M., Kobalka, P., Roy, S., Nagahara, A.H., Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol. 72 (2015), 1139–1147.
235. Ultsch, M.H., Wiesmann, C., Simmons, L.C., Henrich, J., Yang, M., Reilly, D., Bass, S.H., de Vos, A.M., Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC. J. Mol. Biol. 290 (1999), 149–159.
236. Vaegter, C.B., Jansen, P., Fjorback, A.W., Glerup, S., Skeldal, S., Kjolby, M., Richner, M., Erdmann, B., Nyengaard, J.R., Tessarollo, L., Lewin, G.R., Willnow, T.E., Chao, M.V., Nykjaer, A., Sortilin associates with Trk receptors to enhance anterograde transport and neurotrophin signaling. Nat. Neurosci. 14 (2011), 54–61.
237. van Blitterswijk, M., DeJesus-Hernandez, M., Rademakers, R., How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?. Curr. Opin. Neurol. 25 (2012), 689–700.
238. Verhaagen, J., Hermens, W.T., Dijkhuizen, P.A., Holtmaat, A.J., Gispen, W.H., Use of viral vectors to promote neuroregeneration. Clin. Neurosci. 3 (1995), 275–283.
239. Vickers, L.A., Gupta, P.K., The future of dry eye treatment: a glance into the therapeutic pipeline. Ophthalmol. Ther., 2015.
240. Vol'pina, O.M., Medvinskaia, N.I., Kamynina, A.V., Zaporozhskaia Ia, V., Aleksandrova, I., Koroev, D.O., Samokhin, A.N., Volkova, T.D., Arsen'ev, A.S., Bobkova, N.V., Immunization witha synthetic fragment 155–164 of neurotrophin receptor p75 prevents memory loss and decreases beta-amyloid level in mice with experimentally induced Alzheimer's disease. Bioorg. Khim. 40 (2014), 451–457.
241. Wang, D.Y., Chan, W.M., Tam, P.O., Baum, L., Lam, D.S., Chong, K.K., Fan, B.J., Pang, C.P., Gene mutations in retinitis pigmentosa and their clinical implications. Clin. Chim. Acta 351 (2005), 5–16.
242. Wang, H., Wang, R., Thrimawithana, T., Little, P.J., Xu, J., Feng, Z.P., Zheng, W., The nerve growth factor signaling and its potential as therapeutic target for glaucoma. BioMed Res. Int., 2014, 2014, 759473.
243. Ward, M.S., Khoobehi, A., Lavik, E.B., Langer, R., Young, M.J., Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres. J. Pharm. Sci. 96 (2007), 558–568.
244. Warren Olanow, C., Bartus, R.T., Baumann, T.L., Factor, S., Boulis, N., Stacy, M., Turner, D.A., Marks, W., Larson, P., Starr, P.A., Jankovic, J., Simpson, R., Watts, R., Guthrie, B., Poston, K., Henderson, J.M., Stern, M., Baltuch, G., Goetz, C.G., Herzog, C., Kordower, J.H., Alterman, R., Lozano, A.M., Lang, A.E., Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78 (2015), 248–257.
245. Webster, N.J., Pirrung, M.C., Small molecule activators of the Trk receptors for neuroprotection. BMC Neurosci., 9(Suppl 2), 2008, S1.
246. Wehrman, T., He, X., Raab, B., Dukipatti, A., Blau, H., Garcia, K.C., Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron 53 (2007), 25–38.
247. Weissmiller, A.M., Wu, C., Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl. Neurodegen., 1, 2012, 14.
248. Wen, R., Tao, W., Li, Y., Sieving, P.A., CNTF and retina. Prog. Retin. Eye Res. 31 (2012), 136–151.
249. Wiese, S., Jablonka, S., Holtmann, B., Orel, N., Rajagopal, R., Chao, M.V., Sendtner, M., Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 17210–17215.
250. Wilkie, N., Wingrove, P.B., Bilsland, J.G., Young, L., Harper, S.J., Hefti, F., Ellis, S., Pollack, S.J., The non-peptidyl fungal metabolite L-783,281 activates TRK neurotrophin receptors. J. Neurochem. 78 (2001), 1135–1145.
251. Xia, R., Mao, Z.H., Progression of motor symptoms in Parkinson's disease. Neurosci. Bull. 28 (2012), 39–48.
252. Xu, H., Czerwinski, P., Xia, N., Forstermann, U., Li, H., Downregulation of BDNF expression by PKC and by TNF-alpha in human endothelial cells. Pharmacology 96 (2015), 1–10.
253. Yamada, K., Nitta, A., Hasegawa, T., Fuji, K., Hiramatsu, M., Kameyama, T., Furukawa, Y., Hayashi, K., Nabeshima, T., Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behav. Brain Res. 83 (1997), 117–122.
254. Yang, T., Knowles, J.K., Lu, Q., Zhang, H., Arancio, O., Moore, L.A., Chang, T., Wang, Q., Andreasson, K., Rajadas, J., Fuller, G.G., Xie, Y., Massa, S.M., Longo, F.M., Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One, 3, 2008, e3604.
255. Yanpallewar, S.U., Barrick, C.A., Buckley, H., Becker, J., Tessarollo, L., Deletion of the BDNF truncated receptor TrkB.T1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. PLoS One, 7, 2012, e39946.
256. Yau, J.W., Rogers, S.L., Kawasaki, R., Lamoureux, E.L., Kowalski, J.W., Bek, T., Chen, S.J., Dekker, J.M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R.F., Ikram, M.K., Kayama, T., Klein, B.E., Klein, R., Krishnaiah, S., Mayurasakorn, K., O'Hare, J.P., Orchard, T.J., Porta, M., Rema, M., Roy, M.S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J.M., Varma, R., Wang, J.J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T.Y., Meta-Analysis for Eye Disease Study G, Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35 (2012), 556–564.
257. Yeo, T.T., Chua-Couzens, J., Butcher, L.L., Bredesen, D.E., Cooper, J.D., Valletta, J.S., Mobley, W.C., Longo, F.M., Absence of p75NTR causes increased basal forebrain cholinergic neuron size, choline acetyltransferase activity, and target innervation. J. Neurosci. 17 (1997), 7594–7605.
258. Zaccaro, M.C., Ivanisevic, L., Perez, P., Meakin, S.O., Saragovi, H.U., p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. J. Biol. Chem. 276 (2001), 31023–31029.
259. Zhang, P., Zhou, Z., Combination of bevacizumab and NGF reduces the risk of diabetic retinopathy. Cell Biochem. Biophys., 2015.
260. Zhang, Z., Liu, X., Schroeder, J.P., Chan, C.B., Song, M., Yu, S.P., Weinshenker, D., Ye, K., 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 39 (2014), 638–650.
261. Zhou, W., Li, X., Huang, D., Zhou, W., Li, T., Song, W., No significant effect of 7,8-dihydroxyflavone on APP processing and Alzheimer-associated phenotypes. Current Alzheimer research 12 (2015), 47–52.
262. Ziebell, M., Khalid, U., Klein, A.B., Aznar, S., Thomsen, G., Jensen, P., Knudsen, G.M., Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. Neurobiol. Aging 33:428 (2012), e421–e425.
263. Zuccato, C., Cattaneo, E., Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5 (2009), 311–322.
264. Zuccato, C., Marullo, M., Conforti, P., MacDonald, M.E., Tartari, M., Cattaneo, E., Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 18 (2008), 225–238.